User menu

Perioperative management of patients on direct oral anticoagulants

Bibliographic reference Dubois, Virginie ; Dincq, Anne-Sophie ; Douxfils, Jonathan ; Ickx, Brigitte ; Samama, Charles-Marc ; et. al. Perioperative management of patients on direct oral anticoagulants. In: Thrombosis Journal, Vol. 15, no. 1 (2017), p. 14 (2017)
Permanent URL http://hdl.handle.net/2078.1/184882
  1. Mega Jessica L., Braunwald Eugene, Wiviott Stephen D., Bassand Jean-Pierre, Bhatt Deepak L., Bode Christoph, Burton Paul, Cohen Marc, Cook-Bruns Nancy, Fox Keith A.A., Goto Shinya, Murphy Sabina A., Plotnikov Alexei N., Schneider David, Sun Xiang, Verheugt Freek W.A., Gibson C. Michael, Rivaroxaban in Patients with a Recent Acute Coronary Syndrome, 10.1056/nejmoa1112277
  2. Oral Rivaroxaban for Symptomatic Venous Thromboembolism, 10.1056/nejmoa1007903
  3. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72.
  4. Granger Christopher B., Alexander John H., McMurray John J.V., Lopes Renato D., Hylek Elaine M., Hanna Michael, Al-Khalidi Hussein R., Ansell Jack, Atar Dan, Avezum Alvaro, Bahit M. Cecilia, Diaz Rafael, Easton J. Donald, Ezekowitz Justin A., Flaker Greg, Garcia David, Geraldes Margarida, Gersh Bernard J., Golitsyn Sergey, Goto Shinya, Hermosillo Antonio G., Hohnloser Stefan H., Horowitz John, Mohan Puneet, Jansky Petr, Lewis Basil S., Lopez-Sendon Jose Luis, Pais Prem, Parkhomenko Alexander, Verheugt Freek W.A., Zhu Jun, Wallentin Lars, Apixaban versus Warfarin in Patients with Atrial Fibrillation, 10.1056/nejmoa1107039
  5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
  6. Connolly Stuart J., Ezekowitz Michael D., Yusuf Salim, Eikelboom John, Oldgren Jonas, Parekh Amit, Pogue Janice, Reilly Paul A., Themeles Ellison, Varrone Jeanne, Wang Susan, Alings Marco, Xavier Denis, Zhu Jun, Diaz Rafael, Lewis Basil S., Darius Harald, Diener Hans-Christoph, Joyner Campbell D., Wallentin Lars, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, 10.1056/nejmoa0905561
  7. Lassen Michael Rud, Gallus Alexander, Raskob Gary E., Pineo Graham, Chen Dalei, Ramirez Luz Margarita, Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement, 10.1056/nejmoa1006885
  8. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, investigators A. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807–15.
  9. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–85.
  10. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ, Group R-NIS. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomized, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721–9.
  11. Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009;91:636–44.
  12. Sié Pierre, Samama Charles M., Godier Anne, Rosencher Nadia, Steib Annick, Llau Juan V., Van der Linden Philippe, Pernod Gilles, Lecompte Thomas, Gouin-Thibault Isabelle, Albaladejo Pierre, Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis, 10.1016/j.acvd.2011.09.001
  13. Ferrandis R, Castillo J, de Andres J, Gomar C, Gomez-Luque A, Hidalgo F, Llau JV, Sierra P, Torres LM. The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost. 2013;110:515–22.
  14. Dincq AS, Lessire S, Douxfils J, Dogne JM, Gourdin M, Mullier F. Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. Biomed Res Int. 2014;2014:385014.
  15. Douketis JD, Wang G, Chan N, Eikelboom JW, Syed S, Barty R, Moffat KA, Spencer FA, Blostein M, Schulman S. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost. 2016;14:89–97.
  16. Godier A, Martin AC, Leblanc I, Mazoyer E, Horellou MH, Ibrahim F, Flaujac C, Golmard JL, Rosencher N, Gouin-Thibault I. Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations. Thromb Res. 2015;136:763–8.
  17. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–507.
  18. Faraoni D, Levy JH, Albaladejo P, Samama CM, Groupe d'Interet en Hemostase P. updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care. 2015;19:203.
  19. Albaladejo Pierre, Bonhomme Fanny, Blais Normand, Collet Jean-Philippe, Faraoni David, Fontana Pierre, Godier Anne, Llau Juan, Longrois Dan, Marret Emmanuel, Mismetti Patrick, Rosencher Nadia, Roullet Stéphanie, Samama Charles-Marc, Schved Jean-François, Sié Pierre, Steib Annick, Susen Sophie, Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) – September 2015, 10.1016/j.accpm.2016.09.002
  20. Healey J. S., Eikelboom J., Douketis J., Wallentin L., Oldgren J., Yang S., Themeles E., Heidbuchel H., Avezum A., Reilly P., Connolly S. J., Yusuf S., Ezekowitz M., , Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial, 10.1161/circulationaha.111.090464
  21. Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;129:1850–9.
  22. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. Subcommittee on control of a: when and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:623–7.
  23. Weitz JI, Eikelboom JW. Urgent need to measure effects of direct oral anticoagulants. Circulation. 2016;134:186–8.
  24. Pradaxa : EPAR - Product Information - 28/01/2016 Pradaxa -EMEA/H/C/000829 -II/0089 [ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf ].
  25. Xarelto -EMEA/H/C/000944 -IB/0040/G - Product Information [ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf ].
  26. Eliquis -EMEA/H/C/002148 -R/0034 - Product Information [ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf ].
  27. Lixiana -EMEA/H/C/002629 -IB/0002 - Product information [ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf ].
  28. Lip Gregory Y.H., Nieuwlaat Robby, Pisters Ron, Lane Deirdre A., Crijns Harry J.G.M., Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach, 10.1378/chest.09-1584
  29. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marin F, Palareti G, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working group on thrombosis. Thromb Haemost. 2011;106:997–1011.
  30. Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD, Weiss JP, Osborn JS, Muhlestein JB, Anderson JL, et al. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm. 2015;12:681–6.
  31. Kaatz S, Douketis JD, Zhou H, Gage BF, White RH. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost. 2010;8:884–90.
  32. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e326S–50S.
  33. Spyropoulos A. C., Al-Badri A., Sherwood M. W., Douketis J. D., Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery, 10.1111/jth.13305
  34. Tafur A, Douketis JD. Perioperative anticoagulant management in patients with atrial fibrillation : practical implications of recent clinical trials. Pol Arch Med Wewn. 2015;125:666–71.
  35. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152:578–89.
  36. Eichinger Sabine, Weltermann Ansgar, Minar Erich, Stain Milena, Schönauer Verena, Schneider Barbara, Kyrle Paul Alexander, Symptomatic Pulmonary Embolism and the Risk of Recurrent Venous Thromboembolism, 10.1001/archinte.164.1.92
  37. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458–62.
  38. Tafur A. J., Wysokinski W. E., McBane R. D., Wolny E., Sutkowska E., Litin S. C., Daniels P. R., Slusser J. P., Hodge D. O., Heit J. A., Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients, 10.1093/annonc/mds058
  39. Douketis James D., Perioperative Management of Patients Receiving Anticoagulant or Antiplatelet Therapy: A Clinician-Oriented and Practical Approach, 10.3810/hp.2011.10.921
  40. Cvirn G, Waha JE, Ledinski G, Schlagenhauf A, Leschnik B, Koestenberger M, Tafeit E, Hinghofer-Szalkay H, Goswami N. Bed rest does not induce hypercoagulability. Eur J Clin Investig. 2015;45:63–9.
  41. Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major bleeding risk in Anticoagulated patients with Atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015;38:555–61.
  42. O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36:3258–64.
  43. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387:2302–11.
  44. Kirchhof Paulus, Benussi Stefano, Kotecha Dipak, Ahlsson Anders, Atar Dan, Casadei Barbara, Castella Manuel, Diener Hans-Christoph, Heidbuchel Hein, Hendriks Jeroen, Hindricks Gerhard, Manolis Antonis S., Oldgren Jonas, Popescu Bogdan Alexandru, Schotten Ulrich, Van Putte Bart, Vardas Panagiotis, Agewall Stefan, Camm John, Baron Esquivias Gonzalo, Budts Werner, Carerj Scipione, Casselman Filip, Coca Antonio, De Caterina Raffaele, Deftereos Spiridon, Dobrev Dobromir, Ferro José M., Filippatos Gerasimos, Fitzsimons Donna, Gorenek Bulent, Guenoun Maxine, Hohnloser Stefan H., Kolh Philippe, Lip Gregory Y. H., Manolis Athanasios, McMurray John, Ponikowski Piotr, Rosenhek Raphael, Ruschitzka Frank, Savelieva Irina, Sharma Sanjay, Suwalski Piotr, Tamargo Juan Luis, Taylor Clare J., Van Gelder Isabelle C., Voors Adriaan A., Windecker Stephan, Zamorano Jose Luis, Zeppenfeld Katja, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, 10.1093/eurheartj/ehw210
  45. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, Advisors: Updated European heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2016. Jun 9. pii: ehw058.
  46. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, Advisors: Updated European heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015. Oct;17(10):1467-1507.
  47. Mauprivez C, Khonsari RH, Razouk O, Goudot P, Lesclous P, Descroix V. Management of dental extraction in patients undergoing anticoagulant oral direct treatment: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:e146–55.
  48. Essebag V, Healey JS, Ayala-Paredes F, Kalfon E, Coutu B, Nery P, Verma A, Sapp J, Philippon F, Sandhu RK, et al. Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: the BRUISE CONTROL-2 trial. Am Heart J. 2016;173:102–7.
  49. Madan S, Muthusamy P, Mowers KL, Elmouchi DA, Finta B, Gauri AJ, Woelfel AK, Fritz TD, Davis AT, Chalfoun NT. Safety of anticoagulation with uninterrupted warfarin vs. interrupted dabigatran in patients requiring an implantable cardiac device. Cardiovasc Diagn Ther. 2016;6:3–9.
  50. Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Ronquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogne JM, Mullier F. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost. 2015;113:862–9.
  51. Lessire Sarah, Dincq Anne-Sophie, Douxfils Jonathan, Devalet Bérangère, Nicolas Jean-Baptiste, Spinewine Anne, Larock Anne-Sophie, Dogné Jean-Michel, Gourdin Maximilien, Mullier François, Erratum to “Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants”, 10.1155/2014/347031
  52. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106:868–76.
  53. Jungbauer L, Dobias C, Stollberger C, Weidinger F. The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost. 2010;8:2069–70.
  54. Douketis JD, Wang G, Chan N, Eikelboom JW, Syed S, Barty R, Moffat KA, Spencer FA, Blostein M, Schulman S. Effect of standardized Perioperative Dabigatran interruption on residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost. 2016 Jan;14(1):89–97.
  55. Horlocker Terese T., Wedel Denise J., Rowlingson John C., Enneking F. Kayser, Kopp Sandra L., Benzon Honorio T., Brown David L., Heit John A., Mulroy Michael F., Rosenquist Richard W., Tryba Michael, Yuan Chun-Su, Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy : American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition), 10.1097/aap.0b013e3181c15c70
  56. Cappelleri Gianluca, Fanelli Andrea, Use of direct oral anticoagulants with regional anesthesia in orthopedic patients, 10.1016/j.jclinane.2016.02.028
  57. Bateman BT, Mhyre JM, Ehrenfeld J, Kheterpal S, Abbey KR, Argalious M, Berman MF, Jacques PS, Levy W, Loeb RG, et al. The risk and outcomes of epidural hematomas after perioperative and obstetric epidural catheterization: a report from the multicenter Perioperative outcomes group research consortium. Anesth Analg. 2013;116:1380–5.
  58. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology. 2004;101:950–9.
  59. Rosencher N., Bonnet M.-P., Sessler D. I., Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies : Anaesthesia and antithrombotic agents, 10.1111/j.1365-2044.2007.05195.x
  60. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27:999–1015.
  61. Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, Carraro P, Salomone L, Paniccia R, Paoletti O, et al. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res. 2016;137:178–83.
  62. Narouze S, Benzon HT, Provenzano DA, Buvanendran A, De Andres J, Deer TR, Rauck R, Huntoon MA: Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of pain Medicine, the international Neuromodulation Society, the north American Neuromodulation Society, and the world Institute of Pain. Reg Anesth Pain Med 2015, 40:182-212.
  63. Benzon HT, Avram MJ, Green D, Bonow RO. New oral anticoagulants and regional anaesthesia. Br J Anaesth. 2013;111(Suppl 1):i96–113.
  64. Di Biase L., Burkhardt J. D., Santangeli P., Mohanty P., Sanchez J. E., Horton R., Gallinghouse G. J., Themistoclakis S., Rossillo A., Lakkireddy D., Reddy M., Hao S., Hongo R., Beheiry S., Zagrodzky J., Rong B., Mohanty S., Elayi C. S., Forleo G., Pelargonio G., Narducci M. L., Russo A. D., Casella M., Fassini G., Tondo C., Schweikert R. A., Natale A., Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management: Results From the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial, 10.1161/circulationaha.113.006426
  65. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, Swarup V, Chalhoub F, Atkins D, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2014;63:982–8.
  66. Eitel C, Koch J, Sommer P, John S, Kircher S, Bollmann A, Arya A, Piorkowski C, Hindricks G. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace. 2013;15:1587–93.
  67. Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H, Ishikawa S, Miyoshi A, Okumura S, Ohguchi S, et al. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2015;38:155–63.
  68. Nagao Tomoyuki, Inden Yasuya, Shimano Masayuki, Fujita Masaya, Yanagisawa Satoshi, Kato Hiroyuki, Ishikawa Shinji, Miyoshi Aya, Okumura Satoshi, Ohguchi Shiou, Yamamoto Toshihiko, Yoshida Naoki, Hirai Makoto, Murohara Toyoaki, Feasibility and Safety of Uninterrupted Dabigatran Therapy in Patients Undergoing Ablation for Atrial Fibrillation, 10.2169/internalmedicine.54.3520
  69. Cappato Riccardo, Marchlinski Francis E., Hohnloser Stefan H., Naccarelli Gerald V., Xiang Jim, Wilber David J., Ma Chang-Sheng, Hess Susanne, Wells Darryl S., Juang George, Vijgen Johan, Hügl Burkhard J., Balasubramaniam Richard, De Chillou Christian, Davies D. Wyn, Fields L. Eugene, Natale Andrea, Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation, 10.1093/eurheartj/ehv177
  70. Nagao Tomoyuki, Inden Yasuya, Yanagisawa Satoshi, Kato Hiroyuki, Ishikawa Shinji, Okumura Satoshi, Mizutani Yoshiaki, Ito Tadahiro, Yamamoto Toshihiko, Yoshida Naoki, Hirai Makoto, Murohara Toyoaki, Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation, 10.1016/j.hrthm.2015.04.016
  71. Konduru Sai V., Cheema Aamir A., Jones Philip, Li Yan, Ramza Brian, Wimmer Alan P., Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin, 10.1007/s10840-012-9719-9
  72. Efremidis Michael, Vlachos Konstantinos, Letsas Konstantinos P., Giannopoulos Georgios, Lioni Louiza, Georgopoulos Stamatis, Vadiaka Maria, Deftereos Spyridon, Sideris Antonios, Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation, 10.1016/j.jelectrocard.2015.06.011
  73. Dincq Anne-Sophie, Lessire Sarah, Chatelain Bernard, Gourdin Maximilien, Dogné Jean-Michel, Mullier François, Douxfils Jonathan, Impact of the Direct Oral Anticoagulants on Activated Clotting Time, 10.1053/j.jvca.2016.09.002
  74. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, Fries D, Gorlinger K, Haas T, Imberger G, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30:270–382.
  75. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S, Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N: Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014. Jul 21;35(28):1888-1896.
  76. Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, Kowey PR, Mahaffey KW, Sherwood MW, Chang P, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the outcomes registry for better informed treatment of Atrial fibrillation (ORBIT-AF). Circulation. 2015;131:488–94.
  77. Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113:625–32.
  78. Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014;124:3692–8.
  79. Garcia DA, Baglin TP, Weitz JI, Samama MM. American College of Chest P: Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e24S–43S.
  80. Mar PL, Familtsev D, Ezekowitz MD, Lakkireddy D, Gopinathannair R. Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: review of the literature and recommendations for specific populations and procedures. Int J Cardiol. 2016;202:578–85.
  81. Flaker Greg C., Theriot Paul, Binder Lea G., Dobesh Paul P., Cuker Adam, Doherty John U., Management of Periprocedural Anticoagulation, 10.1016/j.jacc.2016.04.042
  82. TAFUR A. J., McBANE R., WYSOKINSKI W. E., LITIN S., DANIELS P., SLUSSER J., HODGE D., BECKMAN M. G., HEIT J. A., Predictors of major bleeding in peri-procedural anticoagulation management : Predictors of peri-procedural bleeding, 10.1111/j.1538-7836.2011.04572.x
  83. Douxfils J, Mullier F, Dogne JM. Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin Drug Saf. 2015;14:1283–9.
  84. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:1308–13.
  85. Testa S, Legnani C, Tripodi A, Paoletti O, Pengo V, Abbate R, Bassi L, Carraro P, Cini M, Paniccia R, et al: Poor comparability of coagulation screening test with specific measurement in patients on direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost 2016. Nov;14(11):2194-2201.
  86. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104:1263–71.
  87. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, Siguret V, Lecompte T. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2014;111:240–8.
  88. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost. 2013;110:283–94.
  89. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128–39.
  90. Lessire S, Douxfils J, Baudar J, Bailly N, Dincq AS, Gourdin M, Dogne JM, Chatelain B, Mullier F. Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. Thromb Res. 2015;136(3):693–6.
  91. Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Ronquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogne JM, Mullier F. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost. 2014:113.
  92. Mani H, Rohde G, Stratmann G, Hesse C, Herth N, Schwers S, Perzborn E, Lindhoff-Last E. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost. 2012;108:191–8.
  93. Konigsbrugge O, Quehenberger P, Belik S, Weigel G, Seger C, Griesmacher A, Pabinger I, Ay C. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban. Ann Hematol. 2015;94:1463–71.
  94. Lessire S, Douxfils J, Pochet L, Dincq AS, Larock AS, Gourdin M, Dogné JM, Chatelain B, Mullier F. Estimation of rivaroxaban plasma concentrations in the perioperative setting in patients with or without heparin bridging. Clin Appl Thromb Hemost. 2016 Jan 1:1076029616675968; doi: 10.1177/1076029616675968 .
  95. Lessire S, Dincq AS, Douxfils J, Mullier F: Periprocedural management of direct oral anticoagulants should be guided by accurate laboratory tests. Reg Anesth Pain Med 2016 Nov/Dec;41(6):787-788.
  96. Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM. Heparin-calibrated Chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother. 2015;49:777–83.
  97. Douxfils J, Chatelain B, Hjemdahl P, Devalet B, Sennesael AL, Wallemacq P, Ronquist-Nii Y, Pohanka A, Dogne JM, Mullier F. Does the Russell viper venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thromb Res. 2015 May;135(5):852–60.
  98. Exner T., Ellwood L., Rubie J., Barancewicz A., Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study : , 10.1160/th12-11-0842
  99. Altman R, Gonzalez CD. Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. Thromb J. 2014;12:7.
  100. Altman R, Gonzalez CD. Supporting the use of a coagulometric method for rivaroxaban control: a hypothesis-generating study to define the safety cut-offs. Thromb J. 2015;13:26.
  101. Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol. 2016;172:315–36.
  102. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working group on Perioperative Haemostasis (GIHP) - march 2013. Ann Fr Anesth Reanim. 2013;32:691–700.
  103. Godier A, Gouin-Thibault I, Rosencher N, Albaladejo P. Groupe d'Interet en Hemostase P: [management of direct oral anticoagulants for invasive procedures]. J Mal Vasc. 2015;40:173–81.
  104. Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman MV, Jamieson DG, Levy JH, Pollack CV Jr, Spyropoulos AC, Steiner T, et al. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care. 2016;20:115.
  105. Lohrmann GM, Atwal D, Augoustides JG, Askar W, Patel PA, Ghadimi K, Makar G, Gutsche JT, Shamoun FE, Ramakrishna H. Reversal agents for the new generation of oral anticoagulants: implications for the Perioperative physician. J Cardiothorac Vasc Anesth. 2016;30:823–30.
  106. Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M. Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost. 2015;13:1790–8.
  107. Schulman Sam, Ritchie B., Nahirniak S., Gross P.L., Carrier M., Majeed A., Hwang H.-G., Zondag M., Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study, 10.1016/j.thromres.2017.02.010
  108. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–62.
  109. Glund Stephan, Stangier Joachim, Schmohl Michael, Gansser Dietmar, Norris Stephen, van Ryn Joanne, Lang Benjamin, Ramael Steven, Moschetti Viktoria, Gruenenfelder Fredrik, Reilly Paul, Kreuzer Jörg, Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial, 10.1016/s0140-6736(15)60732-2
  110. Glund S., Moschetti V., Norris S., Stangier J., Schmohl M., van Ryn J., Lang B., Ramael S., Reilly P., A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran : , 10.1160/th14-12-1080
  111. Schmohl M., Glund S., Harada A., Imazu S., De Smet M., Moschetti V., Ramael S., Ikushima I., Grünenfelder F., Reilly P., Stangier J., Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers : , 10.1160/th16-05-0385
  112. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373:511–20.
  113. Pollack CV, Reilly PA, van Ryn J, Eikelboom J, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, et al. Idarucizumab for Dabigatran Reversal: Updated Results of the RE-VERSE AD Study. In American Heart Association Scientific Sessions 2016. New Orleans: The American Journal of Managed Care; 2016. http://www.ajmc.com/conferences/aha2016/results-of-the-re-verse-ad-study-confirmidacizumab-efficacy-safety-at-follow-up .
  114. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, et al. Andexanet Alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.
  115. Connors Jean M., Antidote for Factor Xa Anticoagulants, 10.1056/nejme1513258
  116. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371:2141–2.
  117. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, Dishy V, Lanz HJ, Mercuri MF, Noveck RJ, Costin JC. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017;117:238–45.
  118. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Hartter S, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost. 2013;109:596–605.
  119. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, et al. Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–41.
  120. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113:931–42.
  121. Rottenstreich A, Jahshan N, Avraham L, Kalish Y. Idarucizumab for dabigatran reversal - does one dose fit all? Thromb Res. 2016;146:103–4.